Edwards Lifesciences CVP Wayne Markowitz sells $818,957 in shares By Investing.com

Wayne Markowitz, Corporate Vice President (CVP) of JAPAC at Edwards Lifesciences Corp (), sold 9,628 shares of the company’s common stock on July 28, 2026, for a total value of $818,957. The shares were sold at a price of $85.06 per share.

This sale followed Mr. Markowitz’s acquisition of an equal number of common stock shares on the same day, which stemmed from the exercise of employee stock options. He acquired 9,628 shares at a price of $74.02 per share, totaling $712,664.The insider transaction comes as Edwards Lifesciences trades at $83.71, with the stock currently undervalued according to InvestingPro analysis. The company maintains a “GOOD” financial health score, though 14 analysts have recently revised earnings expectations downward. InvestingPro offers access to over 9 additional exclusive tips and comprehensive metrics for deeper investment analysis.

Specifically, Mr. Markowitz exercised 9,628 employee stock options, receiving common stock at an exercise price of $74.02 per share. Following these transactions, Mr. Markowitz directly beneficially owns 21,679.8708 shares of Edwards Lifesciences common stock.

In other recent news, Edwards Lifesciences reported impressive second-quarter earnings, surpassing Wall Street expectations. The company achieved adjusted earnings per share of $0.78, exceeding the consensus estimate of $0.74, alongside revenue of $1.74 billion, which beat forecasts by $40 million. This strong performance led Edwards Lifesciences to raise its full-year revenue outlook. UBS initiated coverage of Edwards Lifesciences with a buy rating, suggesting confidence in the company’s innovation strategy. Meanwhile, Bernstein raised its price target for the company to $99, maintaining a Market Perform rating. Piper Sandler also increased its price target to $101 and kept an Overweight rating, citing the earnings beat. Additionally, Leerink upgraded Edwards Lifesciences to Outperform, highlighting the momentum in the company’s TAVR segment. These developments reflect a positive outlook from analysts following the company’s robust quarterly results.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.